<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784431</url>
  </required_header>
  <id_info>
    <org_study_id>DNX065.A</org_study_id>
    <nct_id>NCT02784431</nct_id>
  </id_info>
  <brief_title>Pilot Study of the Contour Neurovascular SystemTM</brief_title>
  <official_title>Pilot Study of the Contour Neurovascular SystemTM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerus Endovascular, Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerus Endovascular, Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single arm, multi centre study to evaluate the safety and performance of the&#xD;
      Contour Neurovascular SystemTM in the treatment of intracranial aneurysm (IA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single-arm, multi-centre European study to evaluate the safety and performance&#xD;
      of the Contour Neurovascular SystemTM in the treatment of intracranial aneurysm (IA). Target&#xD;
      aneurysms are unruptured aneurysms requiring endovascular treatment in the anterior and&#xD;
      posterior cerebral circulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    To obtain clinical data in EU for CE Mark&#xD;
  </why_stopped>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Major Ipsilateral Stroke/SAH or Death Due to Neurologic Cause Within Six (6) Months After Treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of subjects with major ipsilateral stroke/SAH or death due to neurologic cause within six (6) months after treatment. All neurological events were adjudicated by an independent Medical Monitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occlusion Status of the Target IA</measure>
    <time_frame>6 months (3 patients), 1 year (14 patients), 2 year (2 patients)</time_frame>
    <description>Last known occlusion status of the target IA as judged by an independent core laboratory using the Raymond-Roy occlusion scale (Class 1 - Complete occlusion; Class 2 - Residual neck; Class 3 - Residual aneurysm).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>Contour Neurovascular System placement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of intracranial aneurysm with the Contour Neurovascular System device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Contour Neurovascular System placement</intervention_name>
    <description>Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.</description>
    <arm_group_label>Contour Neurovascular System placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years at screening&#xD;
&#xD;
          2. Unruptured saccular IA in the anterior or posterior circulation with dimensions&#xD;
             consistent with Table 2&#xD;
&#xD;
          3. IA appears suitable for Contour Neurovascular SystemTM device Patient has the&#xD;
             necessary mental capacity to participate and is willing and able to participate in the&#xD;
             study for the duration of the study follow-up and is able to comply with study&#xD;
             requirements Patient able to understand and sign a study-specific informed consent&#xD;
             form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ruptured IA&#xD;
&#xD;
          2. Any other IA that requires treatment in the next year&#xD;
&#xD;
          3. IA width &gt;8.5 or &lt;2 mm&#xD;
&#xD;
          4. IA neck &gt;8 or &lt;2 mm&#xD;
&#xD;
          5. IA minimum height &lt;4mm&#xD;
&#xD;
          6. IA embolisation would most likely cause stroke&#xD;
&#xD;
          7. Target IA contains other devices/implants (e.g., coils)&#xD;
&#xD;
          8. Inability to access the target IA with the microcatheter&#xD;
&#xD;
          9. Any congenital or iatrogenic coagulopathy&#xD;
&#xD;
         10. Platelet count &lt;50,000/microliter&#xD;
&#xD;
         11. Known allergy to platinum, nickel or titanium&#xD;
&#xD;
         12. Known allergy to contrast agents&#xD;
&#xD;
         13. Stenosis of the target IA's parent vessel &gt;50%&#xD;
&#xD;
         14. Taking daily aspirin or other platelet inhibitor (clopidogrel or equivalent) other&#xD;
             than for the target aneurysm&#xD;
&#xD;
         15. Taking any anticoagulants (e.g., warfarin)&#xD;
&#xD;
         16. Abnormal clotting parameters&#xD;
&#xD;
         17. Pregnant, breastfeeding or planning pregnancy in the next 2 years&#xD;
&#xD;
         18. Other medical conditions that could increase the risk of neurovascular procedures&#xD;
             (e.g., liver failure, cancer, etc.) or ability to comply with study requirements&#xD;
             Participating in another study with investigational devices or drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain</keyword>
  <keyword>Intracranial Aneurysm Treatment</keyword>
  <keyword>Endovascular Treatment</keyword>
  <keyword>Brain Aneurysm</keyword>
  <keyword>Neurovascular diseases</keyword>
  <keyword>Aneurysms</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Vascular diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02784431/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treated</title>
          <description>Patients who met the eligibility criteria and underwent an treatment attempt with the Contour Neurovascular System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unsuccessful Implant Attempt</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treated</title>
          <description>Patients who met the eligibility criteria and underwent an treatment attempt with the Contour Neurovascular System.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="43.4" upper_limit="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkish</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Major Ipsilateral Stroke/SAH or Death Due to Neurologic Cause Within Six (6) Months After Treatment.</title>
        <description>Percentage of subjects with major ipsilateral stroke/SAH or death due to neurologic cause within six (6) months after treatment. All neurological events were adjudicated by an independent Medical Monitor.</description>
        <time_frame>6 months</time_frame>
        <population>Patients who were successfully implanted with the Contour device.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated</title>
            <description>Patients who met the eligibility criteria and underwent an treatment attempt with the Contour Neurovascular System.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Major Ipsilateral Stroke/SAH or Death Due to Neurologic Cause Within Six (6) Months After Treatment.</title>
          <description>Percentage of subjects with major ipsilateral stroke/SAH or death due to neurologic cause within six (6) months after treatment. All neurological events were adjudicated by an independent Medical Monitor.</description>
          <population>Patients who were successfully implanted with the Contour device.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occlusion Status of the Target IA</title>
        <description>Last known occlusion status of the target IA as judged by an independent core laboratory using the Raymond-Roy occlusion scale (Class 1 - Complete occlusion; Class 2 - Residual neck; Class 3 - Residual aneurysm).</description>
        <time_frame>6 months (3 patients), 1 year (14 patients), 2 year (2 patients)</time_frame>
        <population>Patients successfully implanted with the Contour device.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated</title>
            <description>Patients who met the eligibility criteria and underwent an treatment attempt with the Contour Neurovascular System.</description>
          </group>
        </group_list>
        <measure>
          <title>Occlusion Status of the Target IA</title>
          <description>Last known occlusion status of the target IA as judged by an independent core laboratory using the Raymond-Roy occlusion scale (Class 1 - Complete occlusion; Class 2 - Residual neck; Class 3 - Residual aneurysm).</description>
          <population>Patients successfully implanted with the Contour device.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Class 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year (9 patients), 6 months (5 patients), 6 weeks (4 patients), hospital discharge following index procedure (1 patient).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated</title>
          <description>Patients who met the eligibility criteria and underwent an treatment attempt with the Contour Neurovascular System.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Unrelated to device or procedure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device deployment issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other - Not related to device or procedure</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early by the Sponsor due to slow enrollment and a change in regulatory strategy. Less than 50% of the planned sample size was enrolled and none of the subjects had been followed for the planned 5 years.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lori E Adels, Ph.D.</name_or_title>
      <organization>Cerus Endovascular</organization>
      <phone>510-651-4000 ext 109</phone>
      <email>lori.adels@cerusendo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

